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Vaccination is the best method for the prevention and control of influenza. Vaccination can reduce illness and
lessen severity of infection. This review focuses on how currently licensed influenza vaccines are generated in
the U.S., why the biology of influenza poses vaccine challenges, and vaccine approaches on the horizon that
address these challenges.Influenza viruses are members of the Orthomyxoviridae family
and are comprised of segmented negative-sense single-
stranded RNA genomes. Infection with an influenza virus can
result in a sudden onset of fever, cough, rhinitis, malaise, head-
ache, and sore throat following an incubation period of 1 to
3 days. There are three genera of influenza viruses (A, B,
and C) that are divided based on antigenic differences in the
viral nucleoprotein (NP) and matrix protein (M). Both influenza
A and B viruses result in annual epidemics, with an attack
rate of 5%–10% and 20%–30% in adults and in children
each year, respectively (WHO, 2014). This results in 3 to
5 million infections annually and 250,000 to 500,000 excess
deaths worldwide (WHO, 2014). Influenza A viruses from zoo-
notic sources can also result in occasional pandemics; four
have occurred within the past 100 years (Taubenberger and
Kash, 2010).
The influenza A and B virus genomes each contain eight gene
segments. Influenza A viruses are further divided based on the
antigenic properties of their surface glycoproteins into 16 hem-
agglutinin (HA) and 9 neuraminidase (NA) subtypes. While only
a subset of these have been known to result in human infections,
all have been isolated from their natural hosts—waterfowl and
shorebirds (Yoon et al., 2014). The genomes of two additional
subtypes of HA and NA have recently been sequenced from
bats, but these viruses have not yet been isolated (Tong et al.,
2012, 2013). Two influenza A subtypes (H1N1 and H3N2) and
two antigenically distinct lineages of influenza B viruses currently
co-circulate in humans (Grohskopf et al., 2014).
The best method for the prevention and control of influenza is
vaccination (WHO, 2014). Vaccination can reduce illness and
lessen severity of infection, particularly in groups at risk for com-
plications of influenza, including young children and the elderly.
This review is focused on how currently licensed influenza vac-
cines are generated in the US, why the biology of influenza poses
vaccine challenges, and vaccine approaches on the horizon that
address these challenges.
Currently Licensed Seasonal Influenza Vaccines
Currently licensed influenza vaccines focus on the production of
antibodies against the viral HA protein, which binds host recep-
tors to mediate viral entry. Strain-specific antibodies produced
against the HA neutralize the virus and prevent infection (Fig-
ure 1). The current seasonal vaccines require annual evaluation
and reformulation to keep pace with the antigenic drift of cir-culating strains. This process is completed twice a year, once
each for the northern and southern hemispheres (WHO, 2014).
Antigenic drift results from mutations that occur because the
error-prone viral RNA-dependent RNA polymerase lacks proof-
reading function, resulting in mutations in the HA and other viral
proteins. Additionally, the HA is under positive selection for anti-
genic escape from neutralization by pre-existing antibodies.
Selection of the vaccine composition for the upcoming season’s
vaccine must take place 7 to 8 months in advance of ‘‘flu sea-
son’’ to accommodate the steps of vaccine production (WHO,
2014).
There are three classes of licensed seasonal vaccines in-
cluding inactivated, live attenuated, and recombinant HA vac-
cines (Grohskopf et al., 2014). All three vaccines are multivalent,
with components representing influenza A and B viruses antici-
pated to circulate in the next influenza season. The inactivated
influenza vaccine (IIV) is a split virion or subunit vaccine that
contains 15 mg of each purified HA protein administered intra-
muscularly or 9 mg of each purified HA protein administered
intradermally (Grohskopf et al., 2014). There is also a higher
dose of antigen available for the elderly population aged 65 years
and older, in which 60 mg of each HA is administered in order to
increase the immunogenicity of the vaccine. The trivalent inacti-
vated vaccine (TIV) contains H1N1 and H3N2 subtypes of influ-
enza A along with the predicted dominant lineage of influenza
B. A recently licensed quadrivalent influenza vaccine (QIV) in-
cludes two lineages of influenza B along with the H1N1 and
H3N2 subtypes of influenza A. The IIVs induce a strain-specific
serum IgG antibody response and are licensed for individuals
aged 6 months and older.
The second licensed vaccine product is the live attenuated
influenza vaccine (LAIV). This vaccine also contains a mixture
of the same four influenza strains as the QIV but is administered
intranasally as a spray. The LAIV contains live viruses with tem-
perature-sensitive and attenuating mutations (Coelingh et al.,
2014). As a result of these mutations, the vaccine virus is
restricted in replication at the temperature of the lower respira-
tory tract but can replicate at the cooler temperature of the nasal
cavity. Vaccination with LAIV results in the production of strain-
specific serum IgG as well as mucosal IgA and T cell responses
(Coelingh et al., 2014). LAIV is also effective against some anti-
genically drifted strains of influenza (Coelingh et al., 2014). The
LAIV is licensed for healthy individuals between the ages of 2
and 49 years (Grohskopf et al., 2014).Cell Host & Microbe 17, March 11, 2015 ª2015 Elsevier Inc. 295
Figure 1. Stages of the Viral Life Cycle and Vaccine Targets
Many stages of viral infection can be targeted by vaccines; the targets of the vaccines described in this review are indicated. Vaccines that elicit an immune
response that blocks a stage in the viral life cycle are shown in red, while vaccines that activate a specific host immune response are shown in green.
Abbreviations: IIV: inactivated influenza vaccine; LAIV: live attenuated influenza vaccine; COBRA: computationally optimized broadly reactive antigen; HA:
hemagglutinin; ADCC: antibody dependent cell cytotoxicity
Cell Host & Microbe
MinireviewThe third licensed product is FluBlok, which is a recombinant
HA vaccine with HA proteins that are expressed in insect cells
from baculovirus vectors. FluBlok is currently licensed for adults
aged 18 to 49 years and can be used in individuals who are
allergic to eggs (Grohskopf et al., 2014). The manufacturing pro-
cess for this vaccine has a shorter timeframe, which would be
valuable during a pandemic response.
The safety of seasonal influenza vaccines is well accepted.
The most common adverse events reported for IIV involve reac-
tions at the site of injection, including pain, redness, and swelling
(Grohskopf et al., 2014). For the LAIV, the most common events
involve a runny nose and nasal congestion, although fever and
sore throat have also been reported in specific age groups
(Grohskopf et al., 2014). Current recommendations in the US
are for annual vaccination in individuals 6 months and older,
with an emphasis on children; persons over 65 years of age;
pregnant women; individuals with chronic health conditions;
and healthcare workers (Grohskopf et al., 2014; WHO, 2014).
Challenges in Optimizing Influenza Vaccines
Although the currently licensed influenza vaccines are effective
in healthy young adults, Table 1 summarizes several challenges
that remain. They include the dependence on embryonated eggs
for vaccine production, the lengthy timeline for vaccine produc-
tion, the need for annual vaccination, the emergence of antigen-
ically novel viruses, the need for improved immunogenicity in the
elderly, and the need for an improved correlate of protection.
Several approaches have been developed to overcome these296 Cell Host & Microbe 17, March 11, 2015 ª2015 Elsevier Inc.challenges and improve the immunogenicity and efficacy of
influenza vaccines.
Dependence on Embryonated Eggs
One disadvantage that is shared by IIV and LAIV is the need for
embryonated eggs for production. A pandemic will likely result in
a higher demand for vaccine, and embryonated eggs may be in
short supply if the pandemic virus is pathogenic for poultry (Han-
noun, 2013). Several new influenza vaccines have been licensed
within recent years that do not rely on production in eggs. Flucel-
vax is a newly licensed vaccine that is produced in a mammalian
cell line and subsequent manufacturing steps are similar to egg-
based IIV (Grohskopf et al., 2014). As mentioned previously, the
recently licensed recombinant HA vaccine FluBlok is expressed
in insect cells. Also, DNA vaccines and virus-like particles (VLPs)
are vaccine strategies that are in clinical development and are
not manufactured in eggs.
Lengthy Timeline for Vaccine Production
The selection of strains to include in annual influenza vaccines is
based on global surveillance of circulating influenza viruses. Pre-
dictions are made months ahead of the arrival of ‘‘flu season’’ in
order to accommodate all the steps of vaccine production,
including the generation of three or four vaccine seed viruses,
amplification, inactivation, purification, and dispensing into vials
for IIV and blending and filling of sprayers for LAIV.
Antigenic characterization of circulating viruses is the most
critical criterion for the selection of vaccine strains. The antigenic
relationship between circulating viruses is determined by hem-
agglutination inhibition (HAI) assays, in which their reactivity is
Table 1. Summary of Current Vaccine Approaches against Influenza Viruses
Vaccine Format Viral Targets Mode of Action Advantages Solution to Vaccine Challenge
Currently Licensed
IIV HA Neutralizing serum antibodies Inactivated vaccine; Low reactivity










Antibodies; CTL activity Non-replicating; No egg requirement Dependence on eggs for production;
Lengthy production time




HA stem Blocks viral fusion; blocks HA
maturation; increases ADCC
Broad protection; Works at multiple
steps in life cycle
Need for annual vaccination; Broader
immune response
Viral Vectors Various viral
epitopes
Increases ADCC; CTL activity Non-replicating; multiple delivery
methods
Lengthy production time
M2 Antibodies M2 Increases ADCC Broad protection; ‘‘Universal vaccine’’ Need for annual vaccination; broader
immune response; emergence of novel
viruses
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reference strains including the previous year’s vaccine virus.
Antigenic change among influenza viruses can be visualized by
antigenic cartography (Smith et al., 2004), which is a computa-
tional tool for the analysis of HAI assay data that provides a
mathematical foundation for quantitative analysis of antigenic
data (University of Cambridge, 2014). Antigenic cartography is
now applied to the selection of strains for influenza vaccines.
The 2009 pandemic revealed the difficulty in producing and
distributing a vaccine against a newly emerged virus within a
short timeframe (Lee et al., 2014). The 2009 H1N1pdm IIV was
not available in time to prevent the second wave of the pandemic
(National Center for Immunization and Respiratory Diseases,
CDC, 2009). One approach to avoid this predicament in the
future would be to stockpile vaccine seed viruses against dif-
ferent subtypes that have pandemic potential. This process in-
volves the selection of representative viruses from each subtype
prioritized based on epidemiological data and testing of the
candidate vaccines in preclinical studies and clinical trials (Coe-
lingh et al., 2014; Subbarao and Joseph, 2007).
Need for Annual Vaccination
The decline in vaccine-specific antibodies and the antigenic drift
of influenza viruses over time necessitates annual revaccination.
Several strategies are being explored to increase the breadth of
protection, or cross-reactivity, of influenza vaccines to avoid the
need for annual revaccination. These include the use of a com-
putationally designed HA sequence, induction of antibodies
directed at the conserved HA stem, immunization with con-
served influenza proteins that target T cell responses, incorpora-
tion of an adjuvant, and strategies that combine different vaccine
platforms in ‘‘prime-boost’’ formats.
One approach aimed to increase the breadth of the antibody
response against the HA protein involves a computationally
optimized broadly reactive antigen, or COBRA HA presented in
a VLP vaccine (Giles and Ross, 2011). The sequence of theCOBRA HA represents a consensus sequence from a vast
collection of influenza viruses that incorporates the most com-
mon amino acid at each position. This retention of conserved re-
gions within the HA results in the generation of cross-reactive
antibodies (Giles et al., 2012a). An H5N1 COBRA vaccine has
been shown to induce broadly reactive antibodies against
multiple clades of H5N1 viruses and results in less pathology
following challenge than a non-consensus VLP vaccine in
nonhuman primates (Giles et al., 2012b).
Another approach to enhance the breadth of the antibody
response is to elicit antibodies directed at the conserved stalk
or stem of the HA. A majority of antibodies elicited during infec-
tion target the immunodominant HA head domain that contains
the receptor binding site and several well-defined antigenic sites
that accumulate mutations as the virus drifts under immune
pressure. The HA stem domain is much more conserved and an-
tibodies targeting this region are more broadly reactive. Based
onphylogenetic analysis HAproteins fall into twogroups; group 1
includes subtypes H1, H2, H5, H6, H8, H9, H11, H12, H13, H16,
H17, and H18 while group 2 includes H3, H4, H7, H10, H14, and
H15 HAs (reviewed in Krammer and Palese, 2013). HA stem an-
tibodies recognize subtypes within the same group, and a few
demonstrate binding across both groups (Krammer and Palese,
2013). These stem antibodies do not block receptor binding and
therefore are not detected by HAI assays (Corti and Lanzavec-
chia, 2013). Stem antibodies are believed to function at several
steps of the viral lifecycle. They can inhibit fusion of the viral
membrane through steric hindrance, inhibit maturation of the vi-
rus if the antibody binds to the uncleaved HA protein, and clear
virally infected cells through antibody-dependent cell-mediated
cytotoxicity (ADCC) (Krammer and Palese, 2013). Stem anti-
bodies are not easily detected after vaccination with IIV but are
found after natural infection in low amounts (Krammer and Pal-
ese, 2013). They are more readily produced following infection
with an antigenically distinct virus and were found in higherCell Host & Microbe 17, March 11, 2015 ª2015 Elsevier Inc. 297
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mer and Palese, 2013; Li et al., 2012; Sangster et al., 2013).
Several vaccine approaches have been designed to elicit stem
antibodies. Such techniques include ‘‘headless HAs’’ that lack
the immunodominant head portion of the protein, sequential im-
munization with chimeric HAs bearing different head domains on
a constant stalk domain to boost stem antibody responses, and
vaccines expressing specific sections of the HA, including the
conserved alpha-helix of the stem or the fusion peptide (Kram-
mer and Palese, 2013).
An alternative method of vaccination has focused on express-
ing additional influenza antigens using viral vectors. Viral vectors
are replication-defective viruses that can express high, sus-
tained levels of antigens (Tripp and Tompkins, 2014). Viral vec-
tors can target specific cell types and allow delivery through
multiple routes, and the vectors themselves can act as adjuvants
to improve the immune response. An example of a viral vectored
influenza vaccine is a modified vaccinia virus Ankara (MVA) ex-
pressing a fusion protein of influenza NP and matrix 1 protein
(M1) that induce T cell responses but not neutralizing antibodies.
In phase I clinical trials, the MVA-NP+M1 vaccine was immuno-
genic in healthy older adults aged 50–85 years, both alone and
combined with seasonal TIV (Antrobus et al., 2014; Antrobus
et al., 2012). Also, a phase 1/2a trial evaluating aMVA-hemagglu-
tinin-based H5N1 vaccine was safe and immunogenic in young
adults, with a booster immunization a year later resulting in a
substantial boost in antibody titers in all recipients (Kreijtz
et al., 2014). Adenoviral vectors have also been utilized to ex-
press the influenza matrix 2 protein (M2) and NP proteins that
induced strong IgA and T cell responses after a mucosal admin-
istration and provided heterosubtypic immunity in mice and fer-
rets (Price et al., 2010).
Another technique to broaden the cross-reactivity of influenza
vaccines is to target T cell responses. The T cell response to in-
fluenza is targeted primarily against the internal proteins of the
virus, including the NP and M1 proteins (Lee et al., 2014). These
viral proteins are highly conserved; therefore, they induce cyto-
toxic T lymphocyte (CTL) responses that aremore cross-reactive
than antibody responses directed at the HA. T cell immunity does
not prevent infection but can reduce the severity and duration of
infection (Lee et al., 2014). The role of T cell immunity in amelio-
rating the severity of disease was demonstrated during the 2009
H1N1 pandemic, where the magnitude of the pre-existing CTL
response inversely correlated with disease severity in individuals
without detectable neutralizing antibody (Sridhar et al., 2013).
Of the already licensed vaccines, LAIV results in higher CTL re-
sponses than IIV (He et al., 2006; Lee et al., 2014).
Including adjuvants to boost and broaden the immune res-
ponse is an additional approach to broaden the immune res-
ponse of vaccines (Lee et al., 2014). Adjuvants can also result
in dose sparing of antigen. Several adjuvants are approved for
use in human vaccines in other countries, but adjuvanted influ-
enza vaccines are not yet approved in the U.S. (Even-Or et al.,
2013). Oil-in-water emulsions that include the sterol squalene,
such as AS03 and MF59 (Lee et al., 2014), activate cells near
the injection site to produce cytokines and chemokines and re-
cruit immune cells to the area. Inclusion of MF59 in H1N1 and
H5N1 IIVs resulted in increased magnitude and altered quality
of the antibody response (Khurana et al., 2010, 2011).298 Cell Host & Microbe 17, March 11, 2015 ª2015 Elsevier Inc.A number of recent studies have also demonstrated the benefit
of prime/boost schedules on the efficacy and strength of the im-
mune response. Some strategies include sequential use of
different vaccine platforms. In mice and ferrets, priming with a
NP and M2 DNA vaccine and boosting with an antigen-matched
mucosal adenoviral vector led to robust IgA and T cell responses
in the lungs andprotected the animals fromchallengewith several
subtypes of influenza A viruses (Price et al., 2009). In phase I
clinical trials priming with an H5 HA DNA vaccine, adenovirus-
vectored vaccine or pLAIV and boosting with a matched inacti-
vated vaccine resulted in enhanced immunogenicity with cross-
reactive antibodies (Babu et al., 2014; Gurwith et al., 2013;
Ledgerwood et al., 2011; Lee et al., 2014; Talaat et al., 2014).
Emergence of Novel Viruses
Although currently available vaccines are effective against sea-
sonal influenza viruses, strain-specific immunity fails to protect
against drifted seasonal influenza viruses or from antigenically
novel pandemic viruses. Within the last century there have
been four influenza pandemics associated with high infection
and mortality rates—in 1918, 1957, 1968, and most recently in
2009 (Taubenberger and Kash, 2010)—caused by viruses that
were antigenically distinct from the circulating seasonal strains
of the period. Antigenic shift can result in a pandemic when novel
influenza A viruses infect the human population and have the ca-
pacity for human-to-human transmission. Pigs and domestic
poultry have served as zoonotic sources for influenza viruses
of novel antigenicity entering into the human population (Tau-
benberger and Kash, 2010). Several other subtypes of influenza
A virus (including H5N1, H7N9, and H9N2, among others) have
also resulted in sporadic human infections but have lacked the
ability for sustained human-to-human transmission, and there-
fore have not led to a pandemic.
Both the IIV and LAIV platforms have been utilized in the devel-
opment of pandemic (p) influenza vaccines for use in the event of
emergence of novel subtypes from zoonotic sources. The pIIV
vaccines have typically displayed low immunogenicity and
required high antigen doses, multiple vaccinations, or the inclu-
sion of adjuvants to achieve serum antibody responses that are
predicted to be protective (Baz et al., 2013; Nicholson et al.,
2001; Treanor et al., 2001). On initial evaluation, pLAIV were
found to be variably immunogenic in phase I clinical trials (Coe-
lingh et al., 2014). However, recent data demonstrate that H5N1
and H7N7 pLAIV established a robust long-term B cell memory
(Babu et al., 2014; Talaat et al., 2010; Talaat et al., 2014). None-
theless, pLAIV cannot be used until a pandemic is imminent in or-
der to avoid reassortment of the vaccine virus with circulating
influenza viruses (Jin and Subbarao, 2015).
Our inability to predict the subtype that will cause the next
influenza pandemic and the delay in delivery of the 2009 pan-
demic vaccine has increased interest in a ‘‘universal vaccine’’
that will produce more broadly cross-reactive immunity and
will not require annual updates (Subbarao and Matsuoka,
2013). The two leading candidates for universal vaccines include
the highly conserved stem of the HA and the M2 protein. The HA
stem approach was discussed earlier (Krammer and Palese,
2013). The M2 protein is displayed on the surface of the virion
and acts as an ion channel that is critical for uncoating of the vi-
rus upon entry. During natural infection, antibodies are elicited
against all of the surface viral proteins, including HA, NA, and
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neutralize virus infectivity but can reduce the severity of infection
by clearing infected cells through antibody-dependent cell-
mediated cytotoxicity (ADCC). Although M2 antibodies induced
by natural infection are rare and short lived, they have been
shown to provide broad protection against a range of influenza
A viruses in animal models and were immunogenic in phase I
clinical trials (Lee et al., 2014). Vaccines focusing on M2 protein
typically incorporate the protein into a VLP or express the protein
in a recombinant vaccine by fusing the gene encodingM2 or tan-
dem repeats of the ectodomain ofM2 (M2e) to a carrier protein or
molecule (Lee et al., 2014).
Immunosenescence in the Elderly
The elderly are most vulnerable to severe complications from
influenza, but the effectiveness of standard vaccines in this
age group is very poor. The progressive decline in systemic im-
munity with increasing age is referred to as immunosenescence
(Haq andMcElhaney, 2014). Two strategies to enhance immuno-
genicity of IIV in the elderly are to increase the antigen dose or
include an adjuvant. A high-dose IIV, with four times the normal
amount of HA antigen, has been introduced for use in the elderly
(Grohskopf et al., 2014). Inclusion of oil-in-water adjuvants MF59
or AS03 also enhances the immunogenicity of IIV in the elderly
(Haq and McElhaney, 2014).
Systems biology studies define the components of the im-
mune response that result in effective vaccine protection and
can lead to improvements in vaccines (Lambert et al., 2012).
Such studies have uncovered early immune signatures of vac-
cines that are predictive of immunogenicity. Studies of IIV found
the calmodulin-dependent protein kinase IV (CaMKIV) gene,
thought to be involved in calcium-mediated signaling, was
inversely correlated with the final serum antibody titers in vac-
cines (Nakaya et al., 2011). By comparing the responses be-
tween healthy young adults and older adults, these studies can
identify which components of the immune response are affected
by immunosenescence (Lambert et al., 2012).
An Accurate Correlate of Protection
The HAI antibody titer induced by vaccination is currently
accepted as the correlate of protection against influenza. An
HAI titer ofR1:40 in healthy adults is the titer at which approxi-
mately 50%of individuals are protected from infection. However,
some studies have indicated that a higher HAI titer may be
required in children and that T cells may be a better indicator
for protection in the elderly (Black et al., 2011; Haq and McElha-
ney, 2014). In addition, serum HAI antibody titer is not a reliable
correlate of protection for seasonal and pandemic LAIV vaccines.
LAIV has been shown to be effective in the absence of a robust
serum antibody response (Coelingh et al., 2014). The type and
magnitude of the immune response that will provide optimal pro-
tection against pandemic influenza viruses is unknown. Further-
more, although safety and immunogenicity of pandemic vaccines
are assessed in clinical trials, efficacy is inferred from studies in
animal models or by extrapolation from experience with human
influenza virus vaccines (Subbarao and Joseph, 2007). The HAI
antibody titer also fails to take into account other aspects of im-
mune memory against the virus, including the contribution of
non-neutralizing antibodies and T cell responses to protection.
Amore comprehensive correlate of protection is needed to better
interpret influenza vaccine efficacy.Conclusions and Future Prospects
Licensedseasonal TIV and LAIVdisplayed ameanefficacy of 60%
in healthy adults and 83% in children, respectively, in recentmeta-
analyses (Ohmit et al., 2013; Osterholm et al., 2012). However,
when the match between the vaccine strain and circulating
epidemic strain is poor, or when a new pandemic virus emerges,
these vaccines fail to provide optimal protection. The IIV does
not induce robust immunity in the elderly, and LAIV is only licensed
for individualsup to theageof49years, leaving themost vulnerable
section of the populationpoorly protected (Grohskopf et al., 2014).
Influenza vaccines must protect all age groups, particularly those
most vulnerable to complications of severe influenza. Ideally,
newvaccinesshould increase thebreadthof the immune response
to include antigenically distinct viruses within the same subtype
and viruses of other subtypes, should not be manufactured in
eggs, and should require less time to manufacture than currently
licensed technologies. The ultimate goal of a universal influenza
vaccine is to protect against all influenza A viruses, obviating the
need for annual revaccination. Several promising approaches are
under development to improve or overcome the drawbacks of
the currently licensed vaccines and to induce broad immunity
against other subtypes of influenza with pandemic potential.
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